HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia.
about
How to select the best available related or unrelated donor of hematopoietic stem cells?Which donor or graft source should you choose for the strongest GVL? Is there really any differenceAdvances in predicting acute GVHDT Cell Receptor Excision Circle (TREC) Monitoring after Allogeneic Stem Cell Transplantation; a Predictive Marker for Complications and Clinical OutcomeExpression profiling of major histocompatibility and natural killer complex genes reveals candidates for controlling risk of graft versus host diseaseRelapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase.Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.Outcomes of patients with myeloid malignancies treated with allogeneic hematopoietic stem cell transplantation from matched unrelated donors compared with one human leukocyte antigen mismatched related donors using HLA typing at 10 loci.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell TrSibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapseHow closely related is graft-vs-leukemia to donor/recipient disparity?In silico Derivation of HLA-Specific Alloreactivity Potential from Whole Exome Sequencing of Stem-Cell Transplant Donors and Recipients: Understanding the Quantitative Immunobiology of Allogeneic TransplantationExpression of activating KIR2DS2 and KIR2DS4 genes after hematopoietic cell transplantation: relevance to cytomegalovirus infectionChronic myelogenous leukemia: role of stem cell transplant in the imatinib era.Risk factors for acute GVHD and survival after hematopoietic cell transplantationOutcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia.One-antigen mismatched related versus HLA-matched unrelated donor hematopoietic stem cell transplantation in adults with acute leukemia: Center for International Blood and Marrow Transplant Research results in the era of molecular HLA typing.Risk Factors, Pattern and Clinical Outcome of Acute Graft Versus Host Disease in Acute Leukemia Patients Undergoing Allogeneic Stem Cell TransplantWhat Next? The Next Transit from Biology to Diagnostics: Next Generation Sequencing for Immunogenetics.TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFR1 levels correlate with better outcomes.Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioningThree-dimensional structure discrepancy between HLA alleles for effective prediction of aGVHD severity and optimal selection of recipient-donor pairs: a proof-of-concept studyPractice variation in physician referral for allogeneic hematopoietic cell transplantation.Multiple mismatches at the low expression HLA loci DP, DQ, and DRB3/4/5 associate with adverse outcomes in hematopoietic stem cell transplantation.Anti-thymocyte globulin for conditioning in matched unrelated donor hematopoietic cell transplantation provides comparable outcomes to matched related donor recipients.The major histocompatibility complex: a model for understanding graft-versus-host disease.Identification of a permissible HLA mismatch in hematopoietic stem cell transplantationRole of allo-SCT for CML in 2010.Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia.Stem cell transplantation as a dynamical system: are clinical outcomes deterministic?The efficacy and safety of rabbit anti-thymocyte globulin vs rabbit anti-T-lymphocyte globulin in peripheral blood stem cell transplantation from unrelated donors.Are alternative donors really still "alternative?".Superior transplantation outcomes of 8/8-matched unrelated donors as well as matched siblings to autologous transplantation for acute myeloid leukemia with intermediate cytogenetics in first remission.Long-term outcomes of HLA-matched sibling compared with mismatched related and unrelated donor hematopoietic stem cell transplantation for chronic phase chronic myelogenous leukemia: a single institution experience in China.Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT.Efficiency of allogeneic hematopoietic SCT from HLA fully-matched non-sibling relatives: a new prospect of exploiting extended family search.Unrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia: a survey on behalf of Eurocord and CLWP of EBMT.Single nucleotide polymorphisms within HLA region are associated with disease relapse for patients with unrelated cord blood transplantation
P2860
Q26744109-746CCE71-4B96-4BE5-BAE7-C0A246FF6BC5Q26823536-4014A09C-A9E9-49ED-B9FA-C7D387D9190DQ27021123-AA685C9C-8D97-452C-B12B-DAD24F736FEAQ28072227-1E6535AE-FDB9-440C-9A9F-B56A60C3E8D0Q28743195-E39D227A-0D18-42DC-B81C-23EFF4CDF116Q33813443-208CE346-9D16-4990-B84D-6963C5C5D855Q33830964-2CF6D66D-C47B-4E05-B463-E4D1F8746414Q33956045-EB36B429-307D-4CFB-9953-2CC39ADBC369Q34044024-ADBBCCEB-660C-494B-BF36-DC4E9E37EDECQ34087133-1534976F-4D61-40E2-A339-FB8712833AE8Q34412313-30AD12CC-C592-4695-88E4-1DAE04241506Q34462528-FF414B95-5F1E-4641-B5BD-2FB8AC3201CBQ35421157-2CDC414A-76CF-417F-B699-FF4B7F929A7CQ35633858-43EF090D-BCBC-419E-9AC9-5AC89684961FQ35651735-29ED5E66-6668-4400-884F-D2B7B1492326Q35953348-B5AC5360-F267-4992-B2CD-93496158FC11Q35969119-1B2B1131-5229-450E-80E6-3CF4BB24350AQ35975019-E3C0ECD5-5C5D-459E-A979-E8199B3301A8Q35998361-C1D7EDD1-1F75-4FE0-AF1C-825840984874Q36236659-B122E95D-C51B-4009-8651-6088C468EDE0Q36319726-D0B166A9-F4B9-49BE-A3E6-971757E1BA5CQ36545617-0E2BEE7F-2F05-4F87-AB35-3E5E4D79E01AQ36547170-39CB7D18-B131-4622-B839-DDE4FEB581CFQ36889775-B0E15764-4798-47F9-B5A9-8E135BDE27B0Q37016397-8092C033-D56D-4CCF-AC9F-D0FC5234915BQ37169090-A994EFBB-C160-40E7-AFF7-CAF88F37F8BBQ37596625-A7BDF607-C7D2-4107-8DD8-19F2EA88D20EQ37763493-87744B2E-E498-4E12-BF2D-464F4887F47FQ37988569-A608B14F-06DB-4FB5-9E68-CAF49885F717Q38292672-CD0BFE7F-401A-4EEB-82AC-2CDF0BBB1899Q40149764-AB7EFC09-5F0E-4404-BD2F-61FD47B51FBBQ41185627-A1AE971C-7CFE-43F3-AED0-58BE6CA36C3AQ43671073-05345A76-9982-4581-BAD6-A40D55DD6449Q44718887-D033DCF4-FDEF-487D-A283-74A0A8B1B8D4Q44919804-2B27B4EA-A6F9-4B7A-BAF2-17C814E9BEE4Q48232157-360F4B0F-6990-419E-9F4A-3893892E6EF9Q53166962-251921A4-7B66-49D9-8899-B6ADCC2A9A6AQ58803537-D9A72D64-B9CA-4B61-B209-CF8CDE54A352
P2860
HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
HLA-identical sibling compared ...... hase chronic myeloid leukemia.
@en
HLA-identical sibling compared ...... hase chronic myeloid leukemia.
@nl
type
label
HLA-identical sibling compared ...... hase chronic myeloid leukemia.
@en
HLA-identical sibling compared ...... hase chronic myeloid leukemia.
@nl
prefLabel
HLA-identical sibling compared ...... hase chronic myeloid leukemia.
@en
HLA-identical sibling compared ...... hase chronic myeloid leukemia.
@nl
P2093
P2860
P921
P356
P1476
HLA-identical sibling compared ...... hase chronic myeloid leukemia.
@en
P2093
Auayporn Nademanee
Carolyn K Hurley
Craig Kollman
Daniel J Weisdorf
Effie W Petersdorf
George B Selby
John P Klein
Joseph H Antin
Mary M Horowitz
Michael D Haagenson
P2860
P304
P356
10.1200/JCO.2008.18.7740
P407
P577
2009-02-17T00:00:00Z